ABCAM Plc Posting of Half Yearly Report (1019T)

TIDMABC

RNS Number : 1019T

ABCAM Plc

24 March 2016

 
 For immediate release   24 March 2016 
 

ABCAM PLC

("Abcam" or "the Company")

Posting of Half-Yearly Report

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that its Interim Report for the six months ended 31 December 2015 has been posted to shareholders and is available at the Company's investor relations website, www.abcamplc.com.

For further information please contact:

 
                                       + 44 (0) 1223 
Abcam                                   696 000 
Suzanne Smith, Chief Legal Officer 
 and Company Secretary 
 Julia Wilson, Investor Relations 
J.P.Morgan Cazenove - Nominated        + 44 (0) 20 
 Advisor & Corporate Broker             7742 4000 
James Mitford / Alex Bruce 
                                       + 44 (0) 20 
FTI Consulting                          3727 1000 
Ben Atwell / Brett Pollard / Natalie 
 Garland-Collins 
 

Notes for editors:

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DOCPGUAWWUPQGQW

(END) Dow Jones Newswires

March 24, 2016 03:01 ET (07:01 GMT)